一分钟看懂
这是一项关于乳腺癌的I 期 / II 期研究，登记的药物或干预包括Zongertinib；Trastuzumab deruxtecan；Trastuzumab emtansine；Trastuzumab；Capecitabine；mFOLFOX6；zanidatamab，当前状态为招募中。登记地点显示中国长春、杭州、哈尔滨、南京等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Zongertinib；Trastuzumab deruxtecan；Trastuzumab emtansine；Trastuzumab；Capecitabine；mFOLFOX6；zanidatamab · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Jilin Province Cancer Hospital · 长春
- The First Hospital of Jilin University · 长春
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Jiangsu Province Hospital · 南京
- Fudan University Shanghai Cancer Center · 上海
- Tianjin Cancer Hospital · 天津
- Henan Cancer Hospital · 郑州
公开的入选条件
- Inclusion criteria:
- * Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the informed consent form (ICF)
- * Cohorts A to K and Cohort O: Documented Human epidermal growth factor receptor 2 overexpressing and/or amplified (HER2+), metastatic breast cancer (mBC) or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcin
- * Cohorts L (L-ext), M, and N (metastatic colorectal cancer (mCRC)): Documented Human epidermal growth factor receptor 2 (HER2) overexpression/amplification according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) gastric
- * For dose optimization and justification (Phase II): Patient must provide tumor tissue from locations not radiated prior to biopsy, if possible, collected through archival tissue
- * History of prior treatment lines in palliative setting:
- For cohorts A, B, C, D, E, F, G, H, I, I-ext, J, J-ext, K and O documented investigator assessed progression after HER2-directed treatment for unresectable locally advanced or metastatic disease (For Cohorts D, H, I (I-ext), J (J-ext)
- patients must have been pretreated with trastuzumab deruxtecan (T-DXd) and have progressed or have been intolerant to previous T-DXd).
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06324357；登记信息更新于 2026-09-16。